ICICI Securities is bearish on Glenmark Pharmaceuticals has recommended sell rating on the stock with a target price of Rs ...

Glenmark Pharmaceuticals is set to become net cash positive through its licensing agreement with AbbVie Inc. This move aims ...

S&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing ...

Choice Institutional Equities has reiterated its positive stance on Glenmark Pharma following a major licensing deal between ...

By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

Motilal Oswal said the deal validates several aspects of Glenmark Pharma such as the strength of IGI's BEAT protein platform ...

Glenmark Pharma's licensing deal with AbbVie will make it cash positive, improving its financial position and liquidity, according to S&P.

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

Glenmark Pharmaceuticals Ltd is quoting at Rs 2235, up 0.4% on the day as on 12:44 IST on the NSE. The stock is up 58.13% in last one year as compared to a 1.63% gain in NIFTY and a 8.9% gain in the ...

Glenmark Pharmaceuticals share price surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...